News
Venetoclax-based regimens showed a trend toward improved survival compared to BTK inhibitors, although subgroup sizes were small.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback